Tag: biotech
-

Novartis Licenses Abogen’s ABO2203 in $7.8B mRNA Deal
Novartis will pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA-encoded CD19×CD3 T-cell engager, while securing options on additional RNA programs in a deal potentially worth approximately $7.8 billion.
-

Anthropic Opens Wet Lab to Test Claude in Biology Experiments
Anthropic has opened a Bay Area wet lab to test how Claude and the Model Hardware Standard can connect AI reasoning with physical biology experiments.
-

AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-

GSK Licenses HUTCHMED’s HMPL-A830 in a Deal Worth Up to $1.295 Billion
GSK licensed HUTCHMED’s preclinical HMPL-A830 for up to $1.295 billion, gaining ex-Greater China rights to a KRAS-EGFR antibody-targeted therapy conjugate designed to combine EGFR-guided delivery with intracellular KRAS inhibition.
-

Novartis’ Pelacarsen Fails Phase 3 Lp(a)HORIZON Despite Lowering Lp(a)
Novartis and Ionis reported that pelacarsen lowered Lp(a) but failed to significantly reduce 4-point MACE in the Phase 3 Lp(a)HORIZON trial, raising new questions about the clinical validity of Lp(a) lowering.
-

Teva’s TEV-‘408 Meets Phase 2a Primary Endpoint in Celiac Disease by Reducing Gluten-Induced Intestinal Damage
Teva’s anti-IL-15 antibody TEV-‘408 met the primary endpoint in a Phase 2a celiac disease study, significantly reducing gluten-induced intestinal damage and limiting intraepithelial lymphocyte expansion versus placebo.
-

Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis
Novartis reported positive Phase 3 results for remibrutinib in both REMODEL-1 and REMODEL-2, with significant reductions in annualized relapse rate versus teriflunomide and no liver safety signal reported across the two studies.
-

Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test
Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a single-biomarker blood test designed to assess Alzheimer’s-related amyloid pathology.

